All In Biotech

Drug Trial Radar · NCT02118792

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Mar 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 764 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

764

Actual

Start

Mar 2014

Primary completion

Apr 2015

Study completion Apr 2015

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Apr 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.

Conditions

  • Dermatitis, Atopic

Interventions

  • AN2728 Topical Ointment, 2%Drug

  • Matching vehicle controlDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISGA) Score at Day 29Time frame: Day 29
  2. Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)Time frame: AEs: Baseline (Day 1) up to Day 29, SAEs: Baseline (Day 1) up to Day 36
  3. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings at Day 8Time frame: Baseline, Day 8
  4. Number of Participants With Clinically Significant Change From Baseline in Vital Signs at Day 36Time frame: Baseline (Day 1), Day 36
  5. Number of Participants With Clinically Significant Laboratory ValuesTime frame: Baseline up to Day 36
  6. Percentage of Participants With Local Tolerability Symptoms at BaselineTime frame: Baseline (Day 1)
  7. Percentage of Participants With Local Tolerability Symptoms at Day 8Time frame: Day 8
  8. Percentage of Participants With Local Tolerability Symptoms at Day 15Time frame: Day 15
  9. Percentage of Participants With Local Tolerability Symptoms at Day 22Time frame: Day 22
  10. Percentage of Participants With Local Tolerability Symptoms at Day 29Time frame: Day 29
  11. Percentage of Participants With Local Tolerability Symptoms at Day 36Time frame: Day 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Anacor Investigational Site

    Henrico, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.